AI Radiology Diagnostic Patents

AI radiology diagnostic patents cover detection/classification-model innovations; triage and workflow innovations; quantification innovations; and training-data, generalization, and integration innovations — with IP held by AI-imaging companies and imaging-equipment vendors (in a field using deep learning to analyze medical images and assist radiologists in detecting, prioritizing, and quantifying disease). WHY AI RADIOLOGY: imaging volumes are exploding while radiologists are scarce — AI can DETECT findings (nodules, hemorrhage, fractures), TRIAGE urgent cases to the top of the worklist (stroke, pulmonary embolism), quantify disease, reduce misses, and speed reporting; AI radiology is the most clinically-deployed area of medical AI (hundreds of FDA-cleared products). MAJOR AI-RADIOLOGY PATENT HOLDERS: AIDOC (acute-finding triage across modalities), VIZ.AI (stroke detection + care coordination/team activation), LUNIT (chest X-ray, mammography), RAD AI (reporting/workflow), ANNALISE.AI, GLEAMER, QURE.AI, HEARTFLOW (FFR-CT cardiac), and imaging vendors GE HealthCare, SIEMENS Healthineers, PHILIPS (AI in scanners/platforms). Detection/classification, triage/workflow, quantification, and data/generalization/integration are the core AI-radiology patent domains — and detection models, triage/care-coordination, generalization, and workflow integration are the open whitespace.

Detection (CADe) innovations; classification (CADx) innovations; triage/prioritization and care-coordination innovations; and workflow/integration and quantification innovations represent core AI-radiology patent domains — and finding disease, prioritizing urgent cases, and fitting into clinical workflow are where deployed value sits. DETECTION (CADe) PATENTS: computer-aided DETECTION — deep-learning models that find/localize findings (lung nodules, brain hemorrhage, fractures, breast lesions) in CT/MRI/X-ray/mammography; model architectures, training, and detection methods (with the §101 caveat that pure 'apply a model to detect' claims face eligibility scrutiny — claim specific technical methods/systems). CLASSIFICATION (CADx) PATENTS: computer-aided DIAGNOSIS/characterization — classifying findings (benign vs malignant, disease grading), risk scoring, and differential support. TRIAGE / PRIORITIZATION / CARE-COORDINATION PATENTS: a high-value, deployed use — automatically FLAGGING urgent findings and re-prioritizing the worklist (Aidoc), and COORDINATING CARE (alerting the stroke team, mobilizing specialists — Viz.ai's care-coordination model); triage + workflow/care-coordination methods are valuable, more-defensible IP (they're concrete system/workflow innovations). WORKFLOW / INTEGRATION / QUANTIFICATION PATENTS: integrating with PACS/RIS/reporting, automated MEASUREMENT/quantification (volumes, scores like FFR-CT, coronary calcium), structured reporting, and notification systems; workflow integration drives adoption. Concrete triage/care-coordination/workflow systems, robust detection/quantification methods, and clinical-integration innovations are the highest-value AI-radiology IP because deployed clinical value (and §101-defensibility) favors specific technical systems and workflow innovations over abstract 'AI detects X' claims.

§101 patent-eligibility, training-data/generalization, and FDA SaMD regulation are defining considerations for AI-radiology IP — they shape what's patentable, what's defensible, and what's deployable. §101 PATENT-ELIGIBILITY: software/AI medical-diagnosis methods face ABSTRACT-IDEA / mathematical-algorithm eligibility scrutiny (Alice/Mayo) — a claim that merely 'uses a neural network to detect disease in an image' risks being deemed an abstract idea/mental process; defensible claims tie the AI to SPECIFIC technical improvements, concrete systems (imaging+processing+workflow), particular architectures/methods, or technical effects (improved image processing, specific triage/notification systems) rather than the abstract result; §101 strategy is central to AI-radiology patenting. TRAINING-DATA / GENERALIZATION PATENTS: AI radiology lives or dies on DATA — large, well-LABELED, diverse datasets; methods for data curation/annotation, learning from limited labels, and crucially GENERALIZATION across different scanners/protocols/sites/populations (models often fail on out-of-distribution data — a key technical and clinical problem); data-efficiency and generalization methods are valuable IP (and proprietary data/models are often the real moat, partly trade-secret). FDA SaMD / REGULATORY: AI diagnostics are SOFTWARE AS A MEDICAL DEVICE (SaMD) requiring FDA clearance (mostly 510(k)/De Novo) — clinical validation, and handling continuously-LEARNING/locked algorithms (the FDA's evolving framework for adaptive AI); regulatory clearance and clinical evidence are essential and often matter MORE than patents for the business. §101-defensible technical claims, generalization/data-efficiency methods, and regulatory/clinical validation are the highest-value strategic considerations because eligibility, generalization, and FDA clearance determine whether AI-radiology IP is valid, robust, and deployable.

AI radiology startup IP strategy must navigate Aidoc/Viz.ai/Lunit and imaging-vendor (GE/Siemens/Philips) portfolios, the §101 ABSTRACT-IDEA eligibility problem (central for AI/software diagnosis), the data/generalization moat (often trade-secret), the FDA SaMD regulatory reality (clearance/validation matter enormously), the crowded detection space, the reimbursement realities, and a landscape where detection/triage/workflow methods, generalization, and integration are the durable assets; understand that abstract 'AI detects disease' is hard to patent (and crowded), so the durable IP is in §101-defensible technical systems, triage/care-coordination/workflow, generalization methods, and (often as trade-secret) proprietary data/models — with FDA clearance and clinical evidence paramount, and that §101-defensibility, data/generalization, regulatory clearance, and workflow value matter as much as patents; identify whitespace in triage/workflow, generalization, and new modalities. AI-RADIOLOGY STARTUP IP STRATEGY: §101 IS CENTRAL — CLAIM CONCRETE TECHNICAL SYSTEMS, NOT ABSTRACT 'AI DETECTS DISEASE': pure 'use a model to detect X' faces abstract-idea rejection — claim specific architectures/methods, technical improvements, and concrete imaging+workflow SYSTEMS (triage/notification/integration) with technical effects; TRIAGE/CARE-COORDINATION/WORKFLOW ARE DEFENSIBLE, HIGH-VALUE IP: concrete systems that prioritize worklists and coordinate care (Aidoc/Viz.ai) are deployed, valuable, and more §101-defensible than abstract detection; DATA AND GENERALIZATION ARE THE REAL MOAT (OFTEN TRADE-SECRET): large labeled diverse datasets and models that GENERALIZE across scanners/sites are the key competitive asset — weigh patent disclosure vs trade secret (proprietary data/models are often kept secret); GENERALIZATION/ROBUSTNESS METHODS ARE VALUABLE PATENTS: handling out-of-distribution data (different scanners/populations) is a real technical problem and patentable; FDA CLEARANCE AND CLINICAL EVIDENCE MATTER MORE THAN PATENTS: SaMD clearance (510(k)/De Novo) and clinical validation gate the business — regulatory/clinical strategy is paramount; DETECTION IS CROWDED — DIFFERENTIATE ON WORKFLOW/OUTCOMES/MODALITY: many detection products exist; differentiate via care-coordination, outcomes, new modalities (e.g., opportunistic screening), or quantification; REIMBURSEMENT DRIVES ADOPTION: securing reimbursement (CPT/NTAP) is a key commercial lever; FOUNDATION/MULTIMODAL MEDICAL-IMAGING MODELS ARE THE FRONTIER: large pretrained medical-imaging models are emerging — methods/data IP; WHEN TO PATENT (OR KEEP SECRET): NOVEL TECHNICAL SYSTEM/METHOD WITH MEASURED PERFORMANCE AND §101 IN MIND: file (or trade-secret) once a method shows measured results (detection/classification accuracy (sensitivity/specificity/AUC) + generalization across sites + triage time-to-notification + workflow/outcome impact + clinical-validation) AND can be claimed as concrete technical innovation — measured accuracy/generalization, workflow/outcome value, and §101-defensible technical novelty are the critical AI-radiology IP metrics; KEY FTO CHECKLIST: Aidoc triage; Viz.ai stroke detection/care-coordination; Lunit/Annalise/Qure detection; HeartFlow FFR-CT; GE/Siemens/Philips imaging-AI; CADe detection model/architecture; CADx classification/risk; triage/worklist-prioritization/care-coordination/notification (defensible system); PACS/RIS/reporting integration; quantification/measurement (FFR-CT/calcium/volume); data curation/annotation/limited-label; generalization/out-of-distribution robustness; §101 abstract-idea/Alice-Mayo eligibility; FDA SaMD 510(k)/De Novo/adaptive-AI; reimbursement; proprietary data/model trade-secret.